Decreasing the risk for major adverse cardiovascular events (eg, myocardial infarction and death) and alleviating symptoms are primary therapeutic goals of percutaneous coronary intervention (PCI) in patients with stable ischemic heart disease (SIHD). Current appropriate use criteria (AUC) developed by national cardiovascular societies classify PCIs as appropriate, maybe appropriate, or rarely appropriate.1 Recently, the International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) trial reported that coronary revascularization did not lower cardiovascular event rates among patients with SIHD2 but did improve the disease-specific health status of patients if they had angina.3 We sought to understand the potential implications of the ISCHEMIA trial on the appropriateness of PCI in a contemporary cohort of patients with SIHD.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Malik AO, Spertus JA, Patel MR, Dehmer GJ, Kennedy K, Chan PS. Potential Association of the ISCHEMIA Trial With the Appropriate Use Criteria Ratings for Percutaneous Coronary Intervention in Stable Ischemic Heart Disease. JAMA Intern Med. Published online September 21, 2020. doi:10.1001/jamainternmed.2020.3181
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: